Argenx’s Forte Buyout Extends the Platform Premium Into M&A

Argenx’s Forte deal shows the platform premium is now reaching biotech M&A, not just venture financings.

Updated

What is this trend?

Biotech buyers are paying up for reusable platforms in M&A, valuing assets that can generate multiple programs, diversify pipelines, and scale beyond a single indication.

  • Argenx paid an ~86% premium for Forte, pricing in a "pipeline-in-a-product" platform.
  • Platform breadth now matters in acquisitions, not just in venture financings.
  • Reusable assets can de-risk pipeline concentration and support long-term growth.
  • Partnerability, reproducibility, and extensibility are becoming valuation drivers.
  • The premium is shifting from promise to control transactions, not just private rounds.

What’s the latest?

Argenx’s July 2026 agreement to buy Forte for $77 per share in cash, or about $2.2 billion of equity value, puts a hard number on the market’s willingness to pay for reusable biotech platforms: the de

Reserved capacity, state-backed biologics execution, and platform-premium M&A reshape dealmaking

How it developed

  1. Platform reproducibility, regulated in vivo editing, and late-stage assets are capturing the capital pool
    • Platform Reproducibility Is Becoming the Financing Premium

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Biotechnology

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.